Lantheus announces FDA approval of Pylarify TruVu injection

Lantheus (LNTH) announced that the FDA has approved Pylarify TruVu injection, a new formulation of its F 18 prostate-specific membrane antigen imaging agent. Pylarify TruVu is indicated for positron emission tomography imaging of prostate-specific membrane antigen positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or suspected recurrence based on elevated serum prostate-specific antigen level. Pylarify TruVu is expected to be commercially available in the fourth quarter of 2026 and will be introduced on a rolling geographic basis.